Immune/inflammatory pathways were expressed at a lower level in BRAF-mutant tumors due to either suppression of immune/inflammation genes in BRAF-mutant tumors or increased expression by the tumor or by infiltrating lymphocytes in BRAF wild-type tumors [136]. This evidence concerns the gene BRAF and neoplasm.